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Background: Pulmonary involvement, manifested as pulmonary arterial hypertension or pulmonary fibrosis, is the
most common cause of death in systemic sclerosis (SSc). We aimed to explore the feasibility of detecting early
pulmonary involvement in SSc using recently developed non-invasive quantitative measures of pulmonary
physiology using cardiovascular magnetic resonance (CMR).
Methods: Twenty-seven SSc patients (9 men, 57 ± 13 years) and 10 healthy controls (3 men, 54 ± 9 years)
underwent CMR to determine the pulmonary blood volume (PBV) and the PBV variation (PBVV) throughout the
cardiac cycle. Patients underwent Doppler echocardiography, high-resolution computed tomography (HRCT), and
pulmonary function testing by spirometry. Comparisons were performed using the unpaired t-test and linear
regression analysis was performed with Pearson’s correlation coefficient (r).
Results: Compared to healthy controls, the PBV indexed to lung volume (PBVI) was lower in patients (16 ± 4 vs 20 ±
5%, p < 0.05). There was no difference in PBV (466 ± 87 vs 471 ± 122 mL, p = 0.91) or PBVV/stroke volume (45 ± 10
vs 40 ± 6%, p = 0.09). There were no significant correlations between PBVI and pulmonary artery pressure
estimated by Doppler (p = 0.08) the lung’s diffusion capacity for carbon monoxide (DLCO) (p = 0.09), vital capacity
(p = 0.45), or pulmonary fibrosis by HRCT (p = 0.74).
Conclusions: This study is the first to measure the PBV in humans using CMR. Compared to healthy controls,
newly diagnosed SSc patients have a reduced amount of blood in the pulmonary vasculature (PBVI) but
unchanged pulmonary vascular distensibility (PBVV/stroke volume). PBVI is unrelated to DLCO, pulmonary artery
pressure, vital capacity, and the presence of pulmonary fibrosis. PBVI may be a novel parameter reflecting vascular
lung involvement in early-stage SSc, and these findings may be consistent with pathophysiological changes of the
pulmonary vasculature.* Correspondence: martin@ugander.com
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The diagnosis of systemic sclerosis (SSc) entails a 10–15%
lifetime risk of developing pulmonary arterial hypertension
(PAH) [1-3]. PAH develops as a result of pulmonary
vascular pathology whereas pulmonary hypertension
may be secondary to severe interstitial lung disease [4].
PAH is diagnosed by right heart catheterization and
pulmonary fibrosis is identified by high-resolution com-
puted tomography (HRCT) of the chest. Increased pul-
monary vascular pressures and progressive pulmonary
fibrosis, if left untreated, often lead to right heart failure
and eventually death. Therefore, early detection of
pathological changes in the lungs is important in order
to stall the progress of disease by medical therapy. The
benefit of early detection of PAH has been exemplified
by the improvement in haemodynamics and survival in
a screening cohort compared to a detection cohort of
SSc patients [5]. Since the introduction of medical treat-
ment with angiotensin-converting enzyme inhibitors in
SSc with renal involvement, pulmonary involvement is
now the leading cause of death in SSc [6]. Furthermore,
pulmonary fibrosis, which may occur in the absence of
skin lesions, [7] may lead to an impaired gas exchange due
to altered physiology in the alveolae. This impairment can
be measured by studying the diffusion capacity for carbon
monoxide in the lungs (DLCO) [8].
Cardiovascular magnetic resonance (CMR) has proven
to be a highly accurate and precise tool for flow quanti-
fication and detection of small changes in blood flow
[9]. Recent developments in CMR include the ability to
quantify the pulmonary blood volume (PBV), as well as
the variation in PBV throughout the cardiac cycle, also
called the PBV variation (PBVV) normalized to the
stroke volume in the pulmonary trunk (PBVV/SV). Dur-
ing systole, the pulmonary blood volume will increase
due to the Windkessel effect. The stiffer the blood ves-
sels, the lower the pulmonary blood volume variation.
Measuring the distensibility in the pulmonary trunk
alone will render information about the distensibility
status of the proximal vessels, whereas the rest of the
pulmonary vasculature will not be accounted for. By
comparison, PBVV/SV is a measure of the global
pulmonary vascular distensibility, and it is not related
to change in pulmonary artery cross-sectional area [10,11].
However, little is known about how these measures are
affected by pulmonary involvement such as that which
occurs in SSc. It has been suggested that SSc can lead to
a hyper-reactivity in the pulmonary vessels similar to
the Raynaud’s phenomenon seen in the peripheral cir-
culation [12]. However, a study assessing pulmonary
haemodynamics during right heart catheterization and
infusion of cold liquids showed no presence of cold
induced vasoconstriction in SSc, and concluded that the
constriction is rather caused by proliferation within thepulmonary arterioles [13]. This constriction in the pul-
monary vessels could theoretically yield a smaller PBV
in both absolute measures and indexed to lung volume
(PBVI). Notably, data are not available to support this
hypothesis. Furthermore, the PBV has previously not
been studied in healthy subjects using CMR. Since an
early detection of pulmonary involvement may have
implication for patient care, the aim of this study was to
explore the clinical usefulness of novel CMR techniques
studying the pulmonary blood pool, including the PBV,
and the PBV variation (PBVV) throughout the cardiac
cycle using CMR, in SSc and healthy controls.
We hypothesized that, compared to healthy individuals,
patients with SSc would have a decreased PBVI due to
arteriolar involvement, and a lower PBVV/SV as a result
of decreased pulmonary vascular distensibility. Therefore,
the aim of this study was to prospectively explore the PBV,
PBVI, and PBVV in healthy controls and patients with
newly diagnosed SSc using CMR.
Methods
Study design
Twenty-seven consecutive newly diagnosed SSc patients,
presenting to the Department of Rheumatology, Lund
University Hospital, Lund and 10 healthy volunteers
underwent CMR using a 1.5-T scanner (Intera, Philips,
Best, the Netherlands) and a five-element cardiac coil.
Out of 27 patients, 18 (67%) were diagnosed with limited
cutaneous SSc, and three (11%) with diffuse cutaneous
SSc. Six patients (22%) fulfilled the criteria for early SSc
suggested by LeRoy [14]. Disease duration was calculated
from first non-Raynaud's manifestation. The healthy
volunteers were recruited by local advertisement. All vol-
unteers had a normal electrocardiogram and did not have
any previous cardiac history or cardiopulmonary medi-
cation. The study was approved by the Lund University
Human Subjects Research Ethics Committee, and all
subjects provided written informed consent. All image
analysis was performed using the Segment software
which is freely available for research use (Segment v1.8,
Medviso, Lund, Sweden, http://segment.heiberg.se) [15].
Pulmonary transit time
The pulmonary transit time (PTT) was defined as the
time for a 2 ml intravenously administered contrast
bolus (gadoterate meglumine, 279.3 mg/ml, Gd-DOTA,
Dotarem, Gothia Medical, Billdal, Sweden) to pass from
the pulmonary trunk to the left atrium (Figures 1 and 2).
The contrast, followed by 20 ml of saline, was injected at
4 ml/s using a power injector. Images were acquired in an
atrial short-axis plane bisecting the left atrium and the
pulmonary trunk using a saturation recovery steady-state
free precession imaging sequence. Typical CMR parame-
ters were: slice thickness 20 mm, pixel size 1.3 × 1.3 mm,
Figure 1 Pulmonary transit time (PTT). Time-resolved atrial short-axis SSFP CMR images (TR/TE 2.5/1.2 ms; flip angle 50°) bisecting the pulmonary
trunk (PT) and the left atrium (LA) acquired during the first pass of an intravenous bolus of CMR contrast agent (Gd-DOTA). Panels A-C show the
passage for 2 mL contrast bolus through the PT to the LA. Contrast intensity was measured in a region of interest in the PT and the LA, respectively.
Time (t) is shown in seconds (s) in the lower corner on right hand side of the respective panel. A: time of contrast bolus injection, B: contrast bolus
passing through PT, and C: arrival in LA. Note the change in signal intensity over time in the respective regions of interest.
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50°. The PTT was defined as the time between the time
points of the weighted mean for each time-intensity curve,
respectively, as previously validated [11].
Pulmonary blood volume
The pulmonary blood volume (PBV) was measured as
the product of the PTT and cardiac output, as previ-
ously described and validated [11]. Cardiac output was
assessed by CMR flow measurement of a cross section
of the pulmonary trunk or aorta using a non-segmented
phase contrast velocity-encoded gradient echo sequence
with retrospective ECG triggering and established ana-
lysis methods [10]. Typical CMR parameters were: slice
thickness 6 mm, frames per cardiac cycle: 35, TR/TE:
8.7/5.3 ms, flip angle 15°, pixel size 1.2 × 1.2 mm,






















Figure 2 Measurement of the pulmonary transit time (PTT). The
plot shows signal intensity (in arbitrary units, a.u.) over time for
regions of interest in the pulmonary trunk (red) and the left atrium
(blue), respectively. The black dotted vertical lines indicate the center
of gravity for the respective curve. The double-headed arrow
indicates the PTT.Pulmonary blood volume variation
Flow measurement of the pulmonary trunk and all the
pulmonary veins, respectively, were acquired as previously
described (Figure 3, panel A and B) [10]. The difference
in arterial and venous blood flow over time (Figure 3,
panel C) was integrated, yielding the cumulative blood
volume in the pulmonary circulation (Figure 3, panel D).
The PBV variation (PBVV) was defined as the difference
between the maximum and the minimum of the cumula-
tive volume variation over the cardiac cycle. Arterial and
venous pulmonary blood flow was obtained using the
same sequence as for cardiac output.
Pulmonary blood volume indexed to lung volume
The pulmonary blood volume indexed to lung volume
(PBVI) was defined as PBV/pulmonary volume. The pul-
monary volume was measured by manual planimetry in
a transverse SSFP CMR image stack covering the lungs
during end-expiratory breathhold (Figure 4). Typical
imaging parameters were: number of slices 50–60, slice
thickness 5 mm, TR/TE: 3.2/1.6 ms, flip angle 80°, pixel
spacing 1.4 × 1.4 mm, temporal resolution (duration of
acquisition per image): 400 ms.
Left and right ventricular functional parameters
Left and right ventricular end diastolic volume, end
systolic volume, stroke volume, and ejection fraction
were measured by CMR and manual planimetry using
established techniques [16]. In patients, right ventricu-
lar endocardical delineation was performed in the axial
plane, in the healthy controls right ventricular delinea-
tion was performed in the short-axis plane. Images
were acquired using a cine SSFP sequence. Typical
CMR parameters included: TR/TE: 2.9/1.5 ms, flip
angle: 60°, frames per cardiac cycle: 30, reconstructed
pixel size: 1.4 × 1.4 mm with an acquisition resolution
of 2.1 × 2.3 mm, slice thickness: 8 mm, no slice gap,
temporal resolution: 40 ms. Body surface area was




































































































Figure 3 Pulmonary blood volume variation (PBVV). This figure
shows the calculation of the pulmonary blood volume variation
(PBVV) in a representative patient. Panel A shows the flow in the
pulmonary trunk. Panel B shows the summed flow in all pulmonary
veins. Panel C shows the difference in arterial and total venous
blood flow. Panel D shows the integral of panel C, yielding the
cumulative volume change over time in the pulmonary circulation.
The PBVV was defined as the maximum change over the cardiac
cycle, indicated by the double-headed arrow in Panel D.
Figure 4 Assessment of the pulmonary volume. Transversal SSFP
CMR was undertaken covering the entire lung field with the patient
in functional end-expiratory state. The pulmonary volume was
measured by planimetry in each slice, typically 50–60 slices. The
figure illustrates a single representative transverse slice through the
thorax. The red region of interest illustrates the region included in
the pulmonary volume in this slice. The delineated area includes the
functional residual capacity, the pulmonary parenchyma, and the
pulmonary vessels within the lung parenchyma, but excluding the
greater proximal pulmonary vessels and the aorta.
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HRCT was performed using a Philips Brilliance 16-slice
or 40-slice CT system (Philips, Best, The Netherlands).
Data was visually assessed with regards to the presence
of fibrosis-related pathology. Fibrosis was defined by
the presence of traction bronchiectasis within areas of
ground-glass opacity, and reticulations [18]. Patients
were compared with regards to presence or absence of
ground-glass opacity and/or reticulations and/or traction
bronchiectasis by HRCT.
Echocardiography included Doppler measurement of
the maximum velocity gradient across the tricuspid valve,
and assessment of inferior vena cava size and variation indiameter during respiration. Central venous pressure was
estimated in increments of 5, 10, or 15 mmHg by an expe-
rienced observer based on caval physiology. Systolic pul-
monary artery pressure was calculated using the tricuspid
velocity gradient and caval physiology [19] using a Philips
Sonos 7500 system (Soma Technology Inc, Bloomfield,
CT, USA). The upper limit by echocardiography for PAH
was 30 mmHg. Patients with suspected PAH also under-
went invasive measurement. An invasive mean pulmonary
arterial pressure of ≥25 mmHg, pulmonary vascular
resistance ≥ 3.0 Woods units, and capillary wedge pres-
sure < 15 mmHg was defined as PAH.
Pulmonary function testing included assessment of the
vital capacity (VC) and the diffusion capacity for carbon
monoxide (DLCO) by the single-breath test.Statistics
Comparisons were performed using GraphPad 6.0 for
Windows (GraphPad Software, Inc, La Jolla, CA, USA).
Following visual inspection of the data, comparisons be-
tween groups was tested using the parametric unpaired
t-test. Differences between groups were also tested using
non-parametric tests and this yielded results with identi-
cal levels of significance in all comparisons. Linear regres-
sion analysis was performed with Pearson’s correlation
coefficient (r). p < 0.05 was deemed statistically significant.
Data are presented as mean ± SD.Results
Subject characteristics are described in Table 1.
Table 1 Subject characteristics
Characteristics SSc Controls
Total (n) 27 10
Male:female ratio 3:6 3:7
Age (y) 57 ± 13 54 ± 9
Body surface area (BSA, m2) 1.81 ± 0.16 1.78 ± 0.21
Heart rate (bpm) 76 ± 11 64 ± 7 †
Cardiac index (L/min/m2) 3.3 ± 0.8 3.5 ± 0.6
LV stroke volume index (mL/m2) 44 ± 11 54 ± 7
LV end diastolic volume index (mL/m2) 72 ± 16 89 ± 10
LV end systolic volume index (mL/m2) 29 ± 9 35 ± 4
LV ejection fraction (%) 61 ± 8 60 ± 3
RV stroke volume index (mL/m2) 42 ± 8 53 ± 7 ‡
RV end diastolic volume index (mL/m2) 79 ± 23 83 ±11
RV end systolic volume index (mL/m2) 37 ± 22 30 ± 7
RV ejection fraction (%) 55 ± 13 64 ± 6
Duration of disease (y) 6 ± 8
Limited cutaneous SSc (n (%)) 18 (67)
Diffuse cutaneous SSc (n (%)) 3 (11)
Early SSc (n (%)) 6 (22)
PAH (n (%)) 1 (4)
LV denotes left ventricle, RV denotes right ventricle. Bpm denotes beats per
minute. Disease duration was calculated from first non-Raynaud's
manifestation. Early SSc denotes patients fulfilling the LeRoy criteria. PAH
denotes pulmonary arterial hypertension verified by right heart catheterization
(defined as mPAP >25 mmHg). Data are presented as mean ± SD. † denotes


















Figure 5 PBVI and PBVV/stroke volume. Results for the pulmonary
blood volume indexed to the lung volume (PBVI) and the pulmonary
blood volume variation divided by the stroke volume (PBVV/SV),
respectively, in percent. Open boxes and circles represent healthy
controls (n = 10), and black boxes and circles represent SSc patients
(n = 27). Circles represent individual data and boxes and error bars
show mean ± SD. Note that there was no difference between healthy
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index, and pulmonary blood volume variation by CMR
The pulmonary blood volume indexed to lung volume
(PBVI) in 27 patients compared to 10 healthy controls
was 16 ± 4 vs 20 ± 5%, p < 0.05 (Figure 5). There were no
difference in PBV (466 ± 87 vs 471 ± 122 mL, p = 0.91)
or PBVV (32 ± 8 vs 33 ± 7 mL, p = 0.69, Figure 6). The
LV stroke volume indexed to BSA in 27 SSc patients
was lower compared to 10 healthy individuals (44 ± 11
vs 54 ± 7 mL/m2, p < 0.05, respectively) (Figure 6).
There was no difference in PBVV/stroke volume in pa-
tients compared to controls (45 ± 10 vs 40 ± 6, p = 0.09,
(Figure 5)). There was no correlation between PBVI and
LV or RV function parameters. There were no correlation
between PBVI and PBVV (patients: r = 0.05, p = 0.81;
controls r = −0.02 p = 0.96; for all: r = 0.05, p = 0.77).0 n=27 n=27 n=10n=10
Figure 6 PBVV and stroke volume. Results for the pulmonary
blood volume variation (PBVV) and stroke volume (SV), respectively,
in mL and mL/m2, respectively. Open circles and boxes represent
healthy controls (n = 10), and black circles and boxes represent SSc
patients (n = 27). Circles represent individual data and boxes and
error bars represent mean ± SD.Echocardigraphy
Twenty-three patients (85%) had a suitable trace. There
was no correlation between the estimated systolic pul-
monary artery pressure assessed by Doppler echocardi-
ography, and the PBVI (p = 0.08, n = 23). The estimatedsystolic pulmonary arterial pressure ranged between
26–94 mmHg.
HRCT
Fifteen out of 24 patients (63%) were classified as having
pulmonary fibrosis-related pathology by HRCT. Patients
with pulmonary fibrosis by HRCT did not differ from
those without pulmonary pathology with regards to
PBVI (17 ± 3 vs 17 ± 5%, p = 0.74) or PBVV/stroke volume
(45 ± 7 vs 44 ± 7%, p = 0.86).
Kanski et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:86 Page 6 of 8
http://jcmr-online.com/content/15/1/86Pulmonary function test
The DLCO was assessed in 23 out of 27 patients (85%)
and the VC was assessed in 25 out of 27 patients (93%).
There were no correlation between the PBVI and DLCO
or VC (p = 0.09 and p = 0.45, respectively).
Interobserver variability
Two observers independently evaluated 10 randomly
selected patient data sets. The interobserver variability
for pulmonary volume, PBV, PBVI, and PBVV was 1 ± 1%,
4 ± 12%, 2 ± 12% and 1 ± 6%, respectively.
Discussion
The major finding in this study is that patients with
newly diagnosed SSc, as a group, have a reduced amount
of blood in the pulmonary vasculature normalized to
lung size (PBVI) but an unaffected pulmonary vascular
distensibility (PBVV/stroke volume), compared to healthy
controls. There was no difference in absolute PBV be-
tween the groups. Furthermore, there was no relationship
between PBVI and systolic pulmonary arterial pressure es-
timated by Doppler echocardiography. It remains unclear
what the mechanisms are, however, our findings are com-
patible with previously suggested pathophysiological
changes in the pulmonary vasculature [12]. Doppler-
estimated pulmonary artery pressure, DLCO, and presence
of pulmonary fibrosis-related pathology measured either
on HRCT or as reduced VC did not influence PBVI. Early
pathophysiological changes in the pulmonary circulation
may be the reason why patients with newly diagnosed SSc
differ in PBVI compared to healthy individuals. Such
changes may be important to recognize as a tool to select
patients eligible for right heart catheterization since an
early diagnosis of PAH is paramount to improve survival
in SSc.
PBV
The current study is, to our knowledge, the first to
measure the PBV by CMR in healthy controls and
patients. The PBV has previously been assessed only in
valvular heart disease using dye-dilution based tech-
niques during invasive cardiac catheterization, radioactive
isotope injection or echocardiography [20-24]. However,
catheterization is associated with complications including
perforation of great vessels, and echocardiography is both
user-dependent and has limited precision when assessing
cardiac output [25].
PBVV and stroke volume
There was a lower absolute stroke volume in SSc pa-
tients compared to healthy controls. This difference
may be related to myocardial disease in the SSc patients.
However, there was no difference in pulmonary vascular
distensibility (PBVV/stroke volume) when comparingthe groups. Previously, the PBVV/stroke volume has
been shown to decrease in pigs that developed increased
pulmonary arterial pressure following experimental
acute myocardial infarction [11]. It appears that the
changes in pulmonary arterial pressure in our cohort of
SSc patients either were not of a magnitude sufficient to
influence PBVV, or may have been the result of a different
pathophysiological process compared to experimental
acute myocardial infarction. PBVV has previously been
measured using nitrous oxide body plethysmography or
catheter-based thermodilution techniques [26,27]. The
currently presented technique using CMR has the advan-
tage that it is non-invasive, and, in contrast to plethysmog-
raphy, measures the PBVV in both the arterial and the
venous vessels.
HRCT and DLCO
Pulmonary fibrosis-related pathology seen on HRCT
may lead to non-perfused pulmonary volumes [18]. This,
per se, could lead to a decrease in the PBVI. However,
there was no difference in PBVI when comparing the
presence or absence of HRCT-verified fibrosis-related
pathology. This suggests that PBVI measures a patho-
physiological mechanism independent of pulmonary
fibrosis. In the very first descriptions of SSc patients
developing PAH, a declining DLCO but normal VC was a
key feature. However, there was no correlation between
the PBVI and DLCO, which suggests that the PBVI may
reflect pulmonary involvement prior to changes severe
enough to alter DLCO.
Interpreting the PBVI
The SSc patients in the present study displayed a wide
range of PBVI values. This may be because the patients
are in different stages of disease. However, some patients
even had a higher value than the controls. This may be
related to left ventricular dysfunction, leading to back-
ward failure and an increased amount of blood in the
pulmonary circulation. There was no correlation be-
tween estimated pulmonary artery pressure and PBVI.
Previously, catheter-based techniques have been used to
show an increased PBV in patients with stenosis or re-
gurgitation in the mitral valve, [22,28] presumably due
to backward failure and distension of the pulmonary
venous and/or pulmonary arterial blood pool. Conse-
quently, the following pathophysiological mechanisms
may apply to patients with SSc. On the one hand,
pulmonary arteriolar proliferation may reduce the PBV,
presumably on the arterial side, while on other hand,
backward failure, if present, may increase the PBV,
presumably on the venous side. Thus, SSc patients with
a decreased arterial blood pool and simultaneous back-
ward failure could hypothetically present with a PBVI
within normal values or higher.
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One limitation of the study may be the accuracy of
measuring PBVV, since the PBVV is derived from up to
6 different flow measurements comprised of one meas-
urement each from the pulmonary artery and at most 5
pulmonary veins, respectively. However, the interobserver
variability between two experienced observers was low,
and a previous study with identical methodology has
shown good correspondence between the volumes of
measured in- and outflow from the pulmonary circula-
tion [10] and excellent agreement between flow-derived
and planimetrically derived volume changes in the heart
[9]. Furthermore, the comparison between the PBVI
and PBVV and pulmonary arterial pressures were made
using Doppler-echocardiography derived pressures. In-
vasive pressures were only acquired in three patients
with suspected PAH, and this is a limitation. Another
limitation is that there currently is no gold standard to
measure the pulmonary volume including the functional
end-expiratory lung volume. Thus, a future comparison
between CMR and computed tomography may be of
value to address this issue. Moreover, test-retest variability
would be of value to perform and this has not been done.
Conclusions
Compared to healthy controls, patients with newly diag-
nosed SSc have, as a group, a reduced amount of blood in
the pulmonary vasculature (PBVI) but an unaffected pul-
monary vascular distensibility (PBVV/stroke volume), not
related to the presence of pulmonary fibrosis-related path-
ology on HRCT, estimated pulmonary artery pressure,
DLCO or reduced VC. This implies that the PBVI may re-
flect the morphology of the SSc lung since the majority of
the patients did not show any clinical sign of pulmonary
involvement. These findings are consistent with an in-
volvement of pulmonary arterioles in SSc. Therefore, in
the case of reduced PBVI, an earlier medical treatment
may be indicated in order to stall the progress of further
pulmonary involvement. Also, this study shows the feasi-
bility of assessing the PBV in healthy individuals and clin-
ical SSc patients by using CMR. Further studies are
justified to assess the clinical utility of PBVI as a non-
invasive diagnostic and prognostic measure of patho-
physiological changes in the pulmonary circulation.
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